Biotechs such as Gilead (NASDAQ:GILD) and Vertex Pharma (NASDAQ:VRTX), with a high local tax bill, a heavy U.S.-based ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

Shares of Gilead Sciences Inc. GILD slid 3.09% to $103.25 Thursday, on what proved to be an all-around favorable trading ...

The settlement, which calls for Gilead to pay the U.S. nearly $177 million and the balance to various states, was approved ...

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

[CNBC] Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions ...

The subdued stock price reaction suggests that Gilead Sciences, Inc.'s (NASDAQ:GILD) strong earnings didn't offer any surprises. We think that investors have missed some encouraging factors ...

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...

Gilead Sciences recently announced a presentation at the EASL Congress focusing on liver disease, with promising research in both hepatitis B and C. This comes alongside solid Q1 earnings results ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...